Cover Image
市場調查報告書

老齡化黃斑部病變 (AMD) 治療藥的市場預測:2016-2021年

Age Related Macular Degeneration Market Forecast 2016-2021

出版商 Labrinth Analytics LTD 商品編碼 359694
出版日期 內容資訊 英文 158 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
老齡化黃斑部病變 (AMD) 治療藥的市場預測:2016-2021年 Age Related Macular Degeneration Market Forecast 2016-2021
出版日期: 2016年03月18日 內容資訊: 英文 158 Pages
簡介

本報告提供全球老齡化黃斑部病變 (AMD) 治療藥的市場相關分析,市場規模的到目前為止的變化,主要企業簡介,領導品牌、各主要國家的收益規模的變化與預測,開發平台分析、預測,影響市場成長因素分析,價格分析,SWOT&大環境分析,未來展望等彙整資料。

第1章 過去的市場資料 (過去4年份)

第2章 主要企業

  • Novartis
  • Merck, Inc
  • Pfizer, Inc.
  • Bayer AG
  • 參天製藥
  • Valent Pharmaceutical Internationa, Inc.
  • Regeneron, Inc.
  • F. Hoffmen, La Roche
  • Allergan PLC
  • Alimera LifeSciences
  • Ampio Pharmaceuticals

第3章 領導品牌的收益預測

  • AMD治療藥的治療:全球市場的成果
  • 全球AMD治療藥市場:收益預測
  • Eylea
  • Lucentis
  • Avastin
  • Macugen
  • 其他

第4章 主要國家市場預測

  • 美國
  • 加拿大
  • 德國
  • 義大利
  • 英國
  • 法國
  • 西班牙
  • 歐洲的其他地區
  • 日本
  • 中國
  • 印度
  • 亞洲的其他地區
  • 巴西
  • 墨西哥
  • 南美的其他地區
  • 全球其他地區

第5章 開發平台分析、預測

  • Novartis
  • Bayer
  • Santen Pharmaceutical Company Ltd.
  • Pfizer, Inc.
  • Roche Holding, Inc.
  • Allergan PLC
  • Ampio Pharmaceuticals

第6章 定性分析

  • 市場動態
  • 價值鏈分析
  • 平均價格分析
  • SWOT分析
  • 大環境分析
  • 藥物、其他的治療方法比較
  • 現在可以利用的藥物的市場方案
  • 未來市場的展望

第7章 表格清單

第8章 圖表清單

第9章 刊載企業、組織

目錄

The global age related macular degeneration drugs market was valued at US$ XXXX m in 2015 and is expected to reach US$ XXXX m in 2021, at a CAGR of XXXX % during 2016-2021. The U.S. was the largest market for age related macular degeneration drugs, accounted for XXXX % of the global market. Avastin was the largest segment in terms of revenue in the global age related macular degeneration drugs market and accounted for XXXX % share in 2015. Rise in aging population, innovative product in the pipeline and growing healthcare infrastructure in the developing nations will boost market growth in the future.

image1

image2

image3

image4

image5

Table of Contents

1. Historical Data

  • 1.1 Age Related Macular Degeneration Market 2012
  • 1.2 Age Related Macular Degeneration Market 2013
  • 1.3 Age Related Macular Degeneration Market 2014
  • 1.4 Age Related Macular Degeneration Market 2015

2. Leading Companies in the World AMD Drugs Market

  • 2.1 Novartis
  • 2.2 Merck, Inc
  • 2.3 Pfizer, Inc.
  • 2.4 Bayer AG
  • 2.5 Santen Pharmaceuticals Company Ltd.
  • 2.6 Valent Pharmaceutical Internationa, Inc.
  • 2.7 Regeneron, Inc.
  • 2.8 F. Hoffmen, La Roche
  • 2.9 Allergan PLC
  • 2.10 Alimera LifeSciences
  • 2.11 Ampio Pharmaceuticals

3. AMD Drugs Treatment by Major Brand, 2015 - 2021

  • 3.1 The Global Market for AMD Drugs Treatments in 2014
  • 3.2 The World AMD Drugs Market: Revenue Forecasts 2015-2026
  • 3.3 Eylea Market Forecast 2016 - 2021
  • 3.4 Lucentis Market Forecast 2016 - 2021
  • 3.5 Avastin Market Forecast 2016 - 2021
  • 3.4 Macugen Market Forecast 2016 - 2021
  • 3.5 Others Market Forecast 2016 - 2021

4. Leading National Markets for the AMD Drugs Market 2016-2021

  • 4.1 North America AMD Drugs Market: Regional Forecast 2016-2021
  • 4.2 The US AMD Drugs Market Forecast 2016-2021
  • 4.3 The Canada AMD Drugs Market Forecast 2016-2021
  • 4.4 The Germany AMD Drugs Market Forecast 2016-2021
  • 4.5 The Italy AMD Drugs Market Forecast 2016-2021
  • 4.6 The U.K. AMD Drugs Market Forecast 2016-2021
  • 4.7 The France Ophthalmic Drugs Market Forecast 2016-2021
  • 4.8 The Spain AMD Drugs Market Forecast 2016-2021
  • 4.9 The rest of Europe AMD Drugs Market Forecast 2016-2021
  • 4.10 The Japan AMD Drugs Market Forecast 2016-2021
  • 4.11 The China AMD Drugs Market Forecast 2016-2021
  • 4.12 The India AMD Drugs Market Forecast 2016-2021
  • 4.13 The rest of Asia AMD Drugs Market Forecast 2016-2021
  • 4.14 The Brazil AMD Drugs Market Forecast 2016-2021
  • 4.15 The Mexico AMD Drugs Market Forecast 2016-2021
  • 4.16 The rest of Latin America AMD Drugs Market Forecast 2016-2021
  • 4.17 The rest of the World AMD Drugs Market Forecast 2016-2021

5. The AMD Drugs Market Pipeline Analysis 2016-2021

  • 5.1 Novartis
  • 5.2 Bayer
  • 5.3 Santen Pharmaceutical Company Ltd.
  • 5.4 Pfizer, Inc.
  • 5.5 Roche Holding, Inc.
  • 5.6 Allergan PLC
  • 5.7 Ampio Pharmaceuticals

6. Qualitative Analysis of the AMD Drugs Market 2016-2026

  • 6.1 Market Dynamics
  • 6.2 Value Chain Analysis
  • 6.3 Average Pricing Analysis
  • 6.4 SWOT Analysis
  • 6.5 Pestle Analysis
  • 6.6 Comparison between drugs and Other Treatment
  • 6.7 Market Scenario for Presently Available Drugs
  • 6.8 Future Market Outlook

7. List of Tables

  • Table 1 Novartis: Historical Sales ($m, AGR%), 2011-2014
  • Table 2 Merck: Historical Sales ($m, AGR%), 2011-2014
  • Table 3 Pfizer: Historical Sales ($m, AGR%), 2011-2014
  • Table 4 Bayer: Historical Sales ($m, AGR%), 2011-2014
  • Table 5 Santen: Historical Sales ($m, AGR%), 2011-2014
  • Table 6 Valent: Historical Sales ($m, AGR%), 2011-2014
  • Table 7 Regeneron: Historical Sales ($m, AGR%), 2011-2014
  • Table 8 Roche: Historical Sales ($m, AGR%), 2011-2014
  • Table 9 Allergan: Historical Sales ($m, AGR%), 2011-2014
  • Table 10 Global Forecast, Revenue ($m), Annual Growth (%), CAGR (%), 2016-2021
  • Table 11 Eylea Forecast, Revenue ($m), Annual Growth (%), CAGR (%), 2016-2021
  • Table 12 Lucentis Forecast, Revenue ($m), Annual Growth (%), CAGR (%), 2016-2021
  • Table 13 Avastin Forecast, Revenue ($m), Annual Growth (%), CAGR (%), 2016-2021
  • Table 14 Macugen Forecast, Revenue ($m), Annual Growth (%), CAGR (%), 2016-2021
  • Table 15 Others Forecast, Revenue ($m), Annual Growth (%), CAGR (%), 2016-2021
  • Table 16 Market Share Analysis by Major Drugs, 2015 (%)
  • Table 17 Market Breakdown by Product: Revenue ($bn), Market Share (%), 2015
  • Table 18 Market Breakdown by Disease Segment: Revenue ($bn), Market Share (%), 2015
  • Table 19 Types of CNV in Wet AMD, Description: Approximate Proportion of Cases (%), 2014
  • Table 20 Wet AMD Segment: Revenue ($bn), AGR (%), CAGR (%), Market Share (%), 2015-2021
  • Table 21 Dry AMD Segment Forecast: Revenue ($bn), AGR (%), CAGR (%), Market Share (%), 2015-2021
  • Table 22 DR Segment Forecast: Revenue ($bn), AGR (%), CAGR (%), Market Share (%), 2015-2020
  • Table 23 North America Forecast, Revenue ($m), Annual Growth (%), CAGR (%), 2016-2021
  • Table 24 The U.S. Forecast, Revenue ($m), Annual Growth (%), CAGR (%), 2016-2021
  • Table 25 Canada Forecast, Revenue ($m), Annual Growth (%), CAGR (%), 2016-2021
  • Table 26 Europe Forecast, Revenue ($m), Annual Growth (%), CAGR (%), 2016-2021
  • Table 27 Germany Forecast, Revenue ($m), Annual Growth (%), CAGR (%), 2016-2021
  • Table 28 France Forecast, Revenue ($m), Annual Growth (%), CAGR (%), 2016-2021
  • Table 29 U.K. Forecast, Revenue ($m), Annual Growth (%), CAGR (%), 2016-2021
  • Table 30 Italy Forecast, Revenue ($m), Annual Growth (%), CAGR (%), 2016-2021
  • Table 31 Spain Forecast, Revenue ($m), Annual Growth (%), CAGR (%), 2016-2021
  • Table 32 Rest of Europe Forecast, Revenue ($m), Annual Growth (%), CAGR (%), 2016-2021
  • Table 33 Asia Forecast, Revenue ($m), Annual Growth (%), CAGR (%), 2016-2021
  • Table 34 Japan Forecast, Revenue ($m), Annual Growth (%), CAGR (%), 2016-2021
  • Table 35 China Forecast, Revenue ($m), Annual Growth (%), CAGR (%), 2016-2021
  • Table 36 India Forecast, Revenue ($m), Annual Growth (%), CAGR (%), 2016-2021
  • Table 37 Rest of Asia Forecast, Revenue ($m), Annual Growth (%), CAGR (%), 2016-2021
  • Table 38 Latin America Forecast, Revenue ($m), Annual Growth (%), CAGR (%), 2016-2021
  • Table 39 Brazil Forecast, Revenue ($m), Annual Growth (%), CAGR (%), 2016-2021
  • Table 40 Mexico Forecast, Revenue ($m), Annual Growth (%), CAGR (%), 2016-2021
  • Table 41 Rest of Latin America Forecast, Revenue ($m), Annual Growth (%), CAGR (%), 2016-2021
  • Table 42 Rest of the World Forecast, Revenue ($m), Annual Growth (%), CAGR (%), 2016-2021
  • Table 43 Market Share Analysis by Country, 2015 (%)
  • Table 44 Novartis Pipeline Analysis
  • Table 45 Pfizer Pipeline Analysis
  • Table 46 Roche Pipeline Analysis
  • Table 47 Santen Pipeline Analysis
  • Table 48 Bayer Pipeline Analysis
  • Table 49 Allergan Pipeline Analysis
  • Table 50 Ampio Pharmaceuticals Pipeline Analysis
  • Table 51 SWOT Analysis of the Ophthalmic Drugs Market
  • Table 52 Pestle Analysis of the Ophthalmic Drugs Market
  • Table 53 Comparison Analysis

8.Lists of Figures

  • Figure 1 Global Ophthalmic Drugs Market Segmentation Overview, 2015
  • Figure 2 Novartis: Historical Sales ($m, AGR%), 2011-2014
  • Figure 3 Merck: Historical Sales ($m, AGR%), 2011-2014
  • Figure 4 Pfizer: Historical Sales ($m, AGR%), 2011-2014
  • Figure 5 Bayer: Historical Sales ($m, AGR%), 2011-2014
  • Figure 6 Santen: Historical Sales ($m, AGR%), 2011-2014
  • Figure 7 Valent: Historical Sales ($m, AGR%), 2011-2014
  • Figure 8 Regeneron: Historical Sales ($m, AGR%), 2011-2014
  • Figure 9 Roche: Historical Sales ($m, AGR%), 2011-2014
  • Figure 10 Allergan: Historical Sales ($m, AGR%), 2011-2014
  • Figure 11 Global Forecast, Revenue ($m), Annual Growth (%), CAGR (%), 2016-2021
  • Figure 12 Eylea Forecast, Revenue ($m), Annual Growth (%), CAGR (%), 2016-2021
  • Figure 13 Lucentis Forecast, Revenue ($m), Annual Growth (%), CAGR (%), 2016-2021
  • Figure 14 Avastin Forecast, Revenue ($m), Annual Growth (%), CAGR (%), 2016-2021
  • Figure 15 Macugen Forecast, Revenue ($m), Annual Growth (%), CAGR (%), 2016-2021
  • Figure 16 Others Forecast, Revenue ($m), Annual Growth (%), CAGR (%), 2016-2021
  • Figure 17 Market Share Analysis by Drugs, 2015 (%)
  • Figure 18 North America Forecast, Revenue ($m), Annual Growth (%), CAGR (%), 2016-2021
  • Figure 19 The U.S. Forecast, Revenue ($m), Annual Growth (%), CAGR (%), 2016-2021
  • Figure 20 Canada Forecast, Revenue ($m), Annual Growth (%), CAGR (%), 2016-2021
  • Figure 21 Europe Forecast, Revenue ($m), Annual Growth (%), CAGR (%), 2016-2021
  • Figure 22 Germany Forecast, Revenue ($m), Annual Growth (%), CAGR (%), 2016-2021
  • Figure 23 France Forecast, Revenue ($m), Annual Growth (%), CAGR (%), 2016-2021
  • Figure 24 U.K. Forecast, Revenue ($m), Annual Growth (%), CAGR (%), 2016-2021
  • Figure 25 Italy Forecast, Revenue ($m), Annual Growth (%), CAGR (%), 2016-2021
  • Figure 26 Spain Forecast, Revenue ($m), Annual Growth (%), CAGR (%), 2016-2021
  • Figure 27 Rest of Europe Forecast, Revenue ($m), Annual Growth (%), CAGR (%), 2016-2021
  • Figure 28 Asia Forecast, Revenue ($m), Annual Growth (%), CAGR (%), 2016-2021
  • Figure 29 Japan Forecast, Revenue ($m), Annual Growth (%), CAGR (%), 2016-2021
  • Figure 30 China Forecast, Revenue ($m), Annual Growth (%), CAGR (%), 2016-2021
  • Figure 31 India Forecast, Revenue ($m), Annual Growth (%), CAGR (%), 2016-2021
  • Table 32 Rest of Asia Forecast, Revenue ($m), Annual Growth (%), CAGR (%), 2016-2021
  • Figure 33 Latin America Forecast, Revenue ($m), Annual Growth (%), CAGR (%), 2016-2021
  • Figure 34 Brazil Forecast, Revenue ($m), Annual Growth (%), CAGR (%), 2016-2021
  • Figure 35 Mexico Forecast, Revenue ($m), Annual Growth (%), CAGR (%), 2016-2021
  • Figure 36 Rest of Latin America Forecast, Revenue ($m), Annual Growth (%), CAGR (%), 2016-2021
  • Figure 37 Rest of the World Forecast, Revenue ($m), Annual Growth (%), CAGR (%), 2016-2021
  • Figure 38 Market Share Analysis by Country (%)

9 Companies and Other Organizations Mentioned

  • EMA (European Medicines Agency)
  • FDA (US Food and Drug Administration)
  • GlaxoSmithKline (GSK)
  • Merck & Co.
  • MHLW (Ministry of Health, Labour, and Welfare)
  • MHRA (Medicines and Healthcare Products Regulatory Agency)
  • NICE (the National Institute for Health and Care Excellence)
  • Novartis
  • Santen
  • Pfizer
  • Prima Biomed
  • Regeneron
  • Roche
  • WHO (World Health Organization)

Many more...

Back to Top